monoclon
antibodi
mab
revolut
current
provid
mani
new
option
treatment
neoplast
inflammatori
diseas
larg
bypass
field
infecti
diseas
one
mab
licens
use
infecti
diseas
although
mani
variou
stage
develop
situat
peculiar
given
serum
therapi
one
first
effect
treatment
microbi
diseas
specif
antibodi
numer
antimicrobi
properti
underdevelop
underutil
mab
therapi
microbi
diseas
variou
complex
explan
includ
current
avail
antimicrobi
drug
small
market
high
cost
microbi
antigen
variat
howev
sign
climat
mab
therapeut
infecti
diseas
chang
given
increas
antibiot
drug
resist
emerg
new
pathogen
microb
therapi
avail
develop
mab
cocktail
formul
current
major
hurdl
widespread
introduct
mab
therapi
microbi
diseas
econom
given
high
cost
immunoglobulin
prepar
rel
small
market
despit
obstacl
numer
opportun
mab
develop
microbi
diseas
develop
radioimmunotherapi
provid
new
option
enhanc
magic
bullet
henc
cautiou
optim
year
ahead
see
mab
clinic
use
microbi
diseas
histor
field
infecti
diseas
larg
miss
monoclon
antibodi
mab
therapeut
revolut
past
decad
contrast
field
oncolog
rheumatolog
mab
provid
new
effect
therapi
one
mab
pathogen
microb
often
drugresist
form
exemplifi
multidrugresist
mdr
mycobacterium
tuberculosi
retic
adopt
mab
therapi
infecti
diseas
intrigu
given
antibodi
therapi
first
effect
antimicrobi
earli
centuri
serum
therapi
use
divers
rang
infecti
diseas
includ
pneumococc
pneumonia
meningococc
mening
erysipela
anthrax
other
success
establish
antibodi
therapi
power
tool
infecti
diseas
unfortun
immunolog
complic
associ
use
heterolog
sera
human
serum
sick
immedi
hypersensit
significantli
limit
use
importantli
problem
serum
therapi
necessarili
appli
mab
therapi
technolog
develop
improv
purif
techniqu
abil
engin
human
mab
greatli
reduc
complic
allow
increas
specif
expand
rang
possibl
target
howev
mani
infecti
diseas
avail
antimicrobi
therapi
prove
much
competit
combin
complex
introduc
mab
clinic
practic
hinder
pace
mabbas
therapeut
advanc
despit
current
underdevelop
potenti
antibodi
therapi
form
mab
vast
especi
combat
microb
resist
antibiot
therapi
emerg
viral
diseas
organ
toxin
respons
bioterrorist
threat
believ
mab
well
pois
import
reagent
new
age
antimicrobi
therapi
review
focu
mab
infecti
diseas
note
sever
recent
review
address
topic
antimicrobi
immunoglobulin
therapi
goal
review
state
field
identifi
area
develop
mabbas
therapi
may
particularli
valuabl
prophylact
therapeut
potenti
immun
serum
discov
behr
kitasato
show
passiv
transfer
antibodi
blood
infect
anim
could
provid
immun
diphtheria
work
led
first
instanc
industri
product
protect
serum
sheep
human
therapi
first
nobel
prize
medicin
behr
immun
anim
sera
hors
sheep
chicken
use
treat
diseas
protect
immun
respons
could
induc
anim
host
vaccin
case
human
host
viral
diseas
human
convalesc
sera
success
use
exampl
earli
serum
individu
recov
measl
use
treat
prevent
infect
serum
anim
peopl
collect
pool
treat
number
infect
streptococc
infect
toxinmedi
diseas
like
diphtheria
overal
serum
effect
diseas
like
pneumococc
pneumonia
meningococc
mening
prompt
administr
serum
associ
significantli
improv
surviv
howev
despit
success
discoveri
antibiot
rapidli
replac
serum
therapi
antibiot
easier
manufactur
less
toxic
patient
produc
consist
result
contrast
serum
therapi
depend
anim
sourc
exhibit
great
lottolot
variat
antibiot
product
industri
process
could
formul
prepar
consist
activ
furthermor
serum
therapi
gener
effect
earli
cours
infect
antibiot
therapi
maintain
efficaci
even
given
late
cours
microbi
diseas
anoth
advantag
antibiot
therapi
could
use
without
specif
diagnosi
use
antibodi
therapi
requir
knowledg
pathogen
respons
diseas
consequ
serum
therapi
unabl
compet
antibiot
develop
new
broadspectrum
antibiot
therapi
displac
antibodybas
therapi
tabl
despit
gener
abandon
serum
therapi
bacteri
diseas
certain
nich
develop
continu
use
prophylaxi
treatment
small
number
viral
toxinmedi
diseas
altern
therapeut
option
point
import
illustr
antibodi
therapi
thrive
certain
situat
lack
competit
treatment
diseas
effect
therapi
exampl
antibodi
prepar
continu
use
prevent
rabi
toxic
snakebit
venom
develop
countri
serum
therapi
often
replac
hyperimmun
serum
pool
human
donor
today
hyperimmun
human
sera
immunoglobulin
use
treat
mani
diseas
includ
caus
cytomegaloviru
cmv
respiratori
syncyti
viru
rsv
hepat
viru
hav
hepat
b
viru
hbv
rabi
vaccinia
vesicular
stomat
viru
vzv
measl
underscor
fact
antibodi
therapi
remain
effect
mean
treatment
compar
hyperimmun
sera
even
modern
antibiot
mab
therapi
mani
advantag
disadvantag
tabl
mab
inher
high
specif
target
sinc
microb
gener
antigen
distinct
human
crossreact
host
tissu
minim
contrast
antibiot
target
harm
microb
host
flora
mab
target
specif
microb
system
administr
affect
resid
benefici
microb
could
prove
signific
advantag
given
increas
report
associ
certain
chronic
diseas
asthma
atopi
even
certain
form
cancer
antimicrobi
drug
use
microbi
specif
mean
mab
unlik
select
drugresist
microb
among
nontarget
microb
abil
specif
target
diseasecaus
microbi
popul
without
select
resist
make
mab
therapi
potenti
superior
current
broadspectrum
antibiot
gener
use
therapi
least
microbi
diseas
caus
singl
microb
increas
preval
rise
cost
treat
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
aureu
vrsa
resist
infect
nosocomi
commun
set
emphas
need
develop
new
strategi
control
infect
serum
therapi
definit
use
immun
seraderiv
immunoglobulin
polyclon
prepar
consist
mani
type
antibodi
minut
fraction
specif
intend
microb
contrast
mab
prepar
consist
one
type
immunoglobulin
defin
specif
singl
isotyp
repres
advantag
disadvantag
mab
compar
polyclon
prepar
one
advantag
mab
virtu
fact
chemic
defin
reagent
exhibit
rel
low
lottolot
variabl
contrast
polyclon
prepar
differ
time
sourc
origin
sinc
differ
host
mount
differ
antibodi
respons
anoth
advantag
mab
prepar
much
greater
activ
per
mass
protein
sinc
immunoglobulin
molecul
specif
desir
target
phenomenon
illustr
report
two
mg
dose
two
mab
provid
protect
tetanu
howev
mab
prepar
lack
variabl
regard
epitop
isotyp
consequ
polyclon
prepar
potenti
greater
biolog
activ
target
multipl
microbi
epitop
provid
variou
effector
function
differ
isotyp
develop
human
human
mab
toxic
agent
also
rel
low
current
technolog
make
product
mab
rel
easi
effect
requir
tissu
cultur
microbi
express
system
oppos
live
human
anim
donor
requir
serum
therapi
henc
potenti
toxic
human
human
mab
compar
antibiot
lower
serum
therapi
especi
heterolog
prepar
mab
therapi
also
much
less
like
inadvert
transmit
infecti
diseas
howev
antibodi
therapi
remain
costli
rel
antimicrobi
drug
consequ
mab
unlik
success
compet
antimicrobi
drug
diseas
cheap
effect
therapi
avail
unless
clear
superior
establish
immunoglobulin
therapi
alon
combin
convent
antimicrobi
therapi
fact
specif
antibodi
often
synergist
convent
antimicrobi
therapi
suggest
combin
therapi
current
antimicrobi
regimen
may
confer
potenti
advantag
rel
either
alon
mab
make
antibiot
effect
research
drive
mab
develop
also
enhanc
area
identifi
new
target
vaccin
develop
regard
effort
develop
mabbas
therapi
potenti
impact
mani
aspect
infecti
diseas
medicin
furthermor
mab
effect
immunocompromis
host
evidenc
efficaci
palivizumab
reduc
hospit
rsvassoci
diseas
preterm
infant
even
set
reduc
immun
respons
mab
function
replac
lost
immun
benefit
host
direct
activ
neutral
consequ
mab
attract
altern
alon
adjunct
current
antimicrobi
therapi
effect
host
differ
state
immun
despit
strength
mab
therapi
inher
limit
cost
factor
alreadi
allud
remain
major
obstacl
widespread
mab
use
antibodi
macromolecul
fragil
perish
requir
refriger
contribut
high
cost
furthermor
mab
requir
system
administr
complic
deliveri
mani
clinic
set
final
mab
usual
use
specif
diagnosi
made
era
broadspectrum
antibiot
reli
upon
heavili
treatment
often
begun
diagnost
identif
diseasecaus
microb
made
howev
recent
advanc
rapid
diagnost
techniqu
provid
hope
earlier
specif
diagnosi
essenti
make
mab
treatment
realiz
even
base
experi
serum
therapi
one
could
anticip
mab
effect
administ
rel
earli
cours
infect
decreas
antibodi
efficaci
time
occur
quickli
durat
infect
increas
highlight
need
rapid
diagnosi
treatment
initi
anoth
theoret
drawback
mab
therapi
reagent
definit
target
singl
epitop
provid
one
type
effector
function
correspond
isotyp
although
specif
mab
strength
microb
undergo
rapid
antigen
variat
pose
signific
hurdl
mab
develop
exampl
high
mutat
rate
certain
virus
enabl
escap
neutral
numer
exampl
literatur
experiment
mab
therapi
result
emerg
escap
variant
result
microbi
mutat
andor
microevolut
problem
may
counterbalanc
select
mab
target
conserv
area
viral
particl
use
mixtur
mab
target
variou
epitop
exampl
combin
therapi
mab
cocktail
prevent
escap
variant
mani
virus
includ
influenza
coronaviru
lymphocyt
choriomening
viru
lcmv
although
cocktail
effect
provid
protect
emerg
resist
mutant
inclus
multipl
immunoglobulin
therapeut
formul
fraught
complex
regulatori
licens
issu
nevertheless
progress
overcom
burdensom
regulatori
issu
evidenc
recent
develop
mab
mixtur
prophylaxi
rabi
target
sever
viru
type
inde
polyclon
sera
may
benefici
due
presenc
multipl
protect
antibodi
cocktail
function
mab
could
provid
protect
target
microbi
strain
singl
one
experi
mab
cocktail
accumul
may
possibl
design
therapeut
combin
includ
multipl
effector
function
form
differ
isotyp
epitop
specif
even
face
obstacl
mab
therapi
boom
area
medicin
clinic
use
repres
market
expect
reach
billion
major
approv
mab
treat
cancer
autoimmun
allerg
condit
shown
consider
success
spawn
mab
gold
rush
antigen
differ
host
microb
make
mab
develop
infecti
diseas
easier
cancer
immun
field
target
often
selfantigen
differenti
express
transform
cell
addit
mab
direct
indirect
antimicrobi
mechan
action
direct
mechan
includ
neutral
toxin
bind
virus
prevent
host
cell
entri
recent
mab
also
shown
directli
bactericid
indirect
mechan
involv
fcmediat
function
modul
inflammatori
respons
promot
opson
phagocytosi
enhanc
complementmedi
effect
wide
array
function
make
mab
potenti
use
varieti
infecti
diseas
despit
advantag
current
one
licens
mab
infecti
diseas
understand
success
instruct
possibl
inher
approach
human
mab
palivizumab
brand
name
synagi
bind
rsv
f
protein
effect
prevent
sever
respiratori
diseas
highrisk
infant
immunocompromis
adult
receiv
regulatori
approv
prior
palivizumab
prophylaxi
rsv
diseas
depend
respigam
rsvigiv
prophylact
polyclon
rsv
hyperimmun
serum
prior
polyclon
prepar
plagu
low
specif
activ
effect
dose
requir
administr
larg
volum
antibodi
problemat
low
weight
infant
palivizumab
obviat
problem
sinc
greater
potenc
polyclon
serum
exampl
show
greater
specif
activ
translat
superior
product
greater
potenc
significantli
reduc
volum
need
deliv
therapeut
dose
infant
improv
treatment
avoid
side
effect
pool
serum
view
opportun
develop
mab
includ
nich
use
would
bring
larg
therapeut
benefit
rel
exist
therapi
although
mani
diseas
mab
therapi
could
make
major
contribut
see
econom
favor
instanc
regard
exquisit
specif
antibodybas
therapi
mean
necessarili
smaller
market
broadspectrum
antimicrobi
therapi
combin
rel
high
cost
produc
deliv
immunoglobulin
therapi
make
market
analysi
mani
reagent
econom
viabl
howev
microbi
diseas
inadequ
therapeut
option
antibodybas
therapi
like
competit
provid
diseas
preval
suffici
size
creat
tenabl
demand
noteworthi
even
diseas
current
adequ
antimicrobi
therapi
new
develop
could
make
mab
attract
exampl
consid
case
antibiot
prophylaxi
group
b
streptococcu
gb
neonat
sepsi
mother
carri
gb
routin
treat
antibiot
result
dramat
reduct
neonat
diseas
howev
antibiot
therapi
affect
infant
microflora
epidemiolog
link
develop
atopi
asthma
children
furthermor
prophylact
antibiot
therapi
select
resist
microb
disturb
flora
manner
could
make
colon
resist
microb
like
could
follow
superinfect
may
even
untoward
consequ
later
life
passiv
antibodi
therapi
gb
also
effect
encumb
problem
alter
flora
consequ
henc
econom
passiv
antibodi
antibiot
prophylaxi
nuanc
simpli
valu
differ
altern
truer
cost
comparison
must
take
account
complic
follow
broadspectrum
therapi
histor
major
target
antibodi
therapi
diseas
caus
encapsul
bacteria
eg
pneumococcu
meningococcu
toxin
eg
diphtheria
tetanu
virus
gener
effort
develop
antibodybas
therapi
focus
diseas
humor
immun
system
known
make
strong
contribut
host
defens
microbi
diseas
efficaci
humor
immun
impli
demonstr
passiv
antibodi
protect
andor
correl
specif
antibodi
resist
diseas
howev
recent
work
establish
mab
effect
even
microb
standard
studi
clearli
establish
role
humor
immun
exampl
sever
mab
gener
effect
intracellular
pathogen
microb
natur
ab
believ
primari
role
host
defens
overal
diseas
current
prevent
vaccin
target
popul
weak
immun
system
exampl
young
old
immunosuppress
immunocompromis
patient
valuabl
develop
mab
therapi
viral
bacteri
toxin
diseas
target
mab
develop
discuss
well
potenti
target
base
need
toward
effort
focus
futur
goal
survey
field
understand
catalogu
ongo
effort
beyond
scope
articl
viral
target
particularli
attract
virus
specif
therapi
potenti
mab
use
neutral
antibodi
prevent
viral
bind
entri
host
cell
make
good
platform
prophylaxi
preemptiv
acut
treatment
viral
ill
sever
current
area
viral
mab
develop
mani
clinic
trial
see
tabl
approv
drug
palivizumab
effect
rsv
diseas
suscept
group
consider
effort
develop
gener
mab
motavizumab
brand
name
numax
numaxyt
motavizumab
engin
increas
affin
induc
somat
hypermut
hope
increas
bind
improv
function
human
current
test
phase
iii
clinic
trial
numaxyt
result
addit
effort
prolong
mab
serum
halflif
anoth
potenti
avenu
mab
develop
furthermor
clinic
trial
underway
test
escal
dose
mab
intramuscular
im
administr
show
improv
deliveri
dose
mab
drug
import
next
step
advanc
therapi
develop
illustr
technolog
advanc
may
improv
exist
success
mab
therapeut
hiv
alway
area
great
interest
mab
therapi
sever
mab
hiv
develop
design
inhibit
viral
entri
reduc
viral
load
hivpati
potenti
prevent
infect
certain
case
viral
entri
inhibitor
mab
target
either
cellular
receptor
cognat
viral
protein
effort
develop
neutral
mab
broader
strain
specif
found
success
target
loop
true
mab
design
infecti
diseas
develop
success
vaccin
would
reduc
need
howev
given
slow
progress
front
hiv
vaccin
develop
mab
research
hiv
field
promis
altern
although
numer
antiretrovir
drug
avail
treatment
hiv
avail
effect
mab
therapi
could
complement
chemotherapi
slow
onset
resist
possibl
enhanc
therapeut
efficaci
anoth
target
mab
develop
cmv
sevirumab
current
assess
treatment
cmv
retin
hivinfect
individu
neonat
congenit
cmv
anoth
import
complic
cmv
infect
reactiv
diseas
distinct
burden
transplant
medicin
cmv
infect
larg
portion
popul
least
adult
us
viru
reactiv
devast
consequ
cours
immunosuppress
solid
organ
hematolog
transplant
patient
must
undergo
use
mab
control
reactiv
area
develop
could
benefit
larg
number
patient
hepat
b
c
viru
hbv
hcv
infect
area
antibodi
therapi
offer
great
hope
help
control
diseas
improv
transplant
success
hepat
remain
lead
indic
liver
transplant
viral
reinfect
transplant
liver
major
complic
two
differ
monoclon
antibodi
clinic
trial
improv
transplant
success
neither
specif
viru
bavituximab
specif
phosphatidylserin
phospholipid
expos
membran
damag
cell
specif
inhibitori
cell
costimul
receptor
use
control
chronic
hepat
infect
particularli
set
hivcoinfect
threat
new
pandem
make
influenza
viru
import
candid
mab
develop
research
current
done
character
human
neutral
antibodi
explor
therapeut
potenti
histor
influenza
viru
extrem
challeng
high
antigen
variabl
howev
progress
made
identifi
antibodi
broadli
neutral
event
new
pandem
mab
could
provid
import
option
diseas
control
sinc
confer
immedi
immun
may
use
prophylaxi
individu
like
expos
infect
consider
excit
follow
discoveri
broadli
crossreact
antibodi
specif
influenza
allow
neutral
differ
viral
strain
includ
avian
human
technolog
exist
plasma
cell
secret
influenzaspecif
antibodi
clone
human
donor
use
gener
high
affin
mab
within
matter
week
anoth
promis
opportun
antibodi
therapi
rabi
current
standard
care
depend
administr
immun
globulin
vaccin
regard
major
innov
develop
mab
cocktail
cocktail
compris
two
mab
specif
two
differ
epitop
rabi
viru
show
good
neutral
activ
vitro
well
toler
patient
success
valid
idea
cocktail
multipl
mab
repres
import
logist
improv
mab
therapi
allow
expand
target
coverag
broader
specif
wider
rang
effector
function
avail
vaccin
specif
therapeut
agent
human
flavivir
infect
outbreak
west
nile
enceph
effort
direct
toward
develop
antibodi
therapi
prophylact
treatment
hyperimmun
prepar
deriv
human
convalesc
sera
protect
mice
west
nile
viru
wnv
set
induc
immunocompromis
onset
enceph
observ
suggest
antibodi
effect
treat
diseas
dissemin
brain
spinal
cord
occur
develop
mab
treatment
wnv
elderli
immunocompromis
patient
might
prevent
debilit
diseas
paralysi
occur
popul
human
mab
structur
envelop
protein
current
clinic
trial
could
provid
new
therapeut
option
wnv
abil
rapidli
identifi
microbi
target
produc
mab
make
feasibl
tool
combat
emerg
situat
excel
exampl
rapid
mab
gener
respons
outbreak
provid
respons
sar
corona
viru
sarscov
earli
respiratori
diseas
due
viru
broke
human
popul
within
year
cellular
receptor
viral
glycoprotein
respons
bind
identifi
earli
neutral
human
mab
develop
test
laboratori
illustr
potenti
speed
benchtobedsid
transit
human
mab
develop
hendra
nipah
virus
paramyxovirus
caus
fatal
hemorrhag
fever
respons
outbreak
late
emerg
diseas
one
area
research
specif
mab
target
protect
efficaci
anim
model
prioriti
area
mab
target
need
pathogen
may
develop
reach
clinic
trial
yet
list
tabl
bacteri
diseas
mediat
toxin
histor
respond
specif
antibodi
consequ
remain
good
target
treatment
toxinneutr
mab
addit
toxinmedi
diseas
recent
studi
shown
specif
mab
alter
cours
bacteri
fungal
infect
immunoglobulin
enhanc
action
antimicrobi
issu
mab
synergi
convent
antimicrobi
drug
particular
import
sinc
develop
mab
adjunct
exist
therapi
attract
possibl
improv
therapeut
outcom
bacteri
infect
sever
mab
target
diseas
clinic
trial
tabl
develop
need
therapeut
tabl
discuss
shigalik
toxin
iib
produc
pathogen
strain
escherichia
coli
respons
organ
damag
hemorrhag
coliti
hemolyt
urem
syndrom
hu
develop
dur
sever
mab
design
neutral
system
toxin
develop
one
current
success
phase
clinic
trial
anoth
toxinmedi
diseas
grow
concern
clostridium
difficil
coliti
usual
result
broadspectrum
antibiot
use
although
oral
antibiot
often
clear
infect
indic
new
hypervirul
strain
emerg
increas
diseas
sever
furthermor
certain
individu
diseas
becom
chronic
mab
toxin
toxin
b
develop
current
test
clinic
trial
laboratori
research
shown
mab
may
act
direct
bind
neutral
toxin
fc
receptor
shown
essenti
mab
protect
presum
increas
endocyt
uptak
toxin
effector
cell
increas
preval
toll
diseas
underscor
danger
antibiot
use
potenti
mab
new
therapi
platform
mab
may
becom
essenti
tool
fight
mani
hospitalacquir
infect
often
antibiot
alreadi
fail
improv
outcom
staphylococc
diseas
exampl
bacteri
diseas
bacterium
diseasemedi
toxin
target
mab
two
mab
clinic
trial
recogn
staphylococc
virul
factor
pagibaximab
chimer
mab
specif
lipoteicho
acid
lta
shown
protect
coagulaseneg
staphylococci
con
aureu
infect
certain
popul
suscept
staphylococc
diseas
low
birth
weight
vlbw
newborn
pagibaximab
current
phase
iii
clinic
trial
prevent
infect
anoth
target
aureu
protein
clump
factor
clfa
target
tefibazumab
brand
name
aurexi
phase
ii
clinic
trial
aureu
bacteremia
two
mab
show
promis
provid
hope
develop
improv
mab
target
staphylococc
speci
alphahemolysin
poreform
cytotoxin
essenti
virul
factor
develop
staphylococc
pneumonia
research
recent
shown
passiv
administr
mab
well
vaccin
elicit
activ
immun
antigen
afford
protect
pneumonia
mous
model
antibodi
neutral
toxin
virus
provid
immedi
defens
mani
biolog
weapon
anthrax
exampl
one
diseas
current
treatment
recommend
inadequ
anthrax
vaccin
current
indic
postexposur
prophylaxi
antibioticresist
strain
bacillu
anthraci
rise
concern
protect
antigen
pa
common
subunit
two
dimer
anthrax
toxin
pa
pair
edema
factor
ef
lethal
factor
lf
form
cellular
toxin
mediat
edema
cell
death
respect
two
mab
specif
pa
current
clinic
trial
anthim
announc
restart
phase
clinic
trial
raxibacumab
current
maintain
us
strateg
nation
stockpil
toxin
clostridium
botulinum
anoth
exampl
extrem
potent
neurotoxin
lead
fatal
respiratori
diseas
capabl
weapon
develop
mab
neutral
toxin
postexposur
treatment
import
avenu
research
one
area
antibodi
therapi
long
provid
therapeut
option
neutral
snake
venom
current
prepar
fall
categori
serum
therapi
immunoglobulin
deriv
heterolog
sourc
one
group
develop
human
singl
chain
variabl
antibodi
fragment
huscfv
phage
display
librari
effect
neutral
neurotoxin
prevent
lethal
mice
illustr
new
mab
technolog
antibodi
format
abl
improv
expand
current
treatment
howev
econom
could
pose
formid
problem
develop
mab
venom
therapi
sinc
number
differ
poison
great
fortun
number
case
rel
fungal
diseas
promis
area
mab
therapi
fungal
diseas
chronic
difficult
treat
carri
high
mortal
morbid
despit
antifung
therapi
group
diseas
mab
therapi
could
find
nich
current
therapi
suboptim
date
one
mab
studi
clinic
treatment
cryptococc
mening
antibodi
reduc
serum
cryptococc
antigen
high
dose
made
econom
unfeas
antibodi
fragment
surfac
heat
shock
protein
show
promis
efficaci
human
candidiasi
phase
iii
trial
recent
broadli
crossreact
mab
fungal
cell
wall
antigen
describ
effect
experiment
aspergillosi
candidiasi
cryptococcosi
anoth
exampl
broadli
activ
antifung
mab
mimic
killer
toxin
action
exquisit
specif
antibodi
target
provid
mean
deliv
harm
cargo
target
concept
long
recogn
oncolog
investig
tri
enhanc
efficaci
antitumor
antibodi
therapi
conjug
antibodi
bacteri
toxin
radioisotop
like
use
mab
therapi
gener
field
infecti
diseas
slow
adopt
strategi
although
consider
experiment
work
done
develop
immunotoxin
target
hivinfect
cell
nevertheless
recent
year
progress
made
develop
radioimmunotherapi
infecti
diseas
radioimmunotherapi
rit
first
develop
cancer
treatment
almost
three
decad
ago
rit
use
antigenantibodi
interact
deliv
radionuclid
eman
lethal
dose
cytotox
radiat
cancer
cell
provid
valuabl
altern
chemotherapi
extern
radiat
beam
therapi
ebrt
rit
success
therapi
certain
cancer
evidenc
recent
approv
mabbas
drug
zevalin
bexxar
mab
label
respect
treatment
relaps
refractori
bcell
nonhodgkin
lymphoma
recent
report
use
rit
initi
treatment
follicular
lymphoma
encourag
thu
make
rit
first
line
therapi
type
cancer
recent
potenti
rit
antimicrobi
strategi
explor
reason
enigmat
could
reflect
lack
awar
difficult
problem
clinic
infecti
diseas
nuclear
medicin
commun
rit
infecti
diseas
commun
last
year
rit
success
adapt
laboratori
treatment
experiment
fungal
bacteri
viral
infect
briefli
review
data
efficaci
safeti
rit
infecti
diseas
potenti
efficaci
rit
infecti
diseas
first
establish
use
cryptococcu
neoforman
cn
cn
major
fungal
pathogen
caus
lifethreaten
meningoenceph
patient
aid
cn
provid
good
system
studi
potenti
use
rit
excel
anim
model
avail
well
character
mab
cn
antigen
exist
immunotherapi
cn
infect
capsul
polysaccharidebind
antibodi
alreadi
clinic
evalu
spite
high
level
circul
polysaccharid
blood
infect
mice
pulmonari
system
anim
model
cn
infect
radiolabel
mab
preferenti
local
site
infect
mab
radiolabel
bi
kill
cn
cell
vitro
thu
provid
basi
vivo
experi
ajcr
mice
infect
system
cn
mice
treat
radiolabel
cnspecif
mab
live
significantli
longer
mice
given
irrelev
label
pb
mice
infect
cn
given
rit
significantli
reduc
fungal
burden
lung
brain
h
treatment
compar
infect
mice
control
group
antimicrobi
rit
approach
subsequ
extend
anoth
human
pathogen
fungu
histoplasma
capsulatum
hc
common
caus
fungal
pneumonia
immunocompromis
patient
treat
hc
vitro
relabel
mab
igm
bind
protein
antigen
surfac
hc
cell
wall
nineti
percent
hc
cell
kill
ci
hcspecif
mab
contrast
incub
hc
radiolabel
control
igm
specif
activ
produc
minim
kill
within
investig
rang
dose
cellular
dosimetri
calcul
base
mean
absorb
dose
cell
show
rit
alphaand
betaemit
radioisotop
approxim
effici
kill
cn
approxim
effici
kill
hc
gamma
radiat
potenti
rit
bacteri
infect
establish
use
streptococcu
pneumonia
import
extracellular
pathogen
good
anim
model
mab
avail
greater
percentag
mice
treat
surviv
rel
control
group
mice
control
group
succumb
bacteremia
day
mice
treat
ci
mice
demonstr
surviv
treatment
radiolabel
well
toler
weight
loss
observ
treat
anim
rit
could
also
potenti
effect
chronic
infect
cell
includ
viral
infect
contrast
rit
fungal
bacteri
diseas
target
microb
rit
viral
infect
infect
mammalian
cell
would
target
thu
provid
gener
strategi
elimin
reservoir
infect
cell
viral
cellular
factori
approach
could
develop
treatment
drugresist
hiv
strain
efficaci
rit
treatment
hiv
infect
vivo
explor
radiolabel
hiv
envelopespecif
human
mab
radiolabel
bi
studi
human
peripher
blood
mononuclear
cell
pbmc
infect
jrcsf
inject
spleen
scid
mice
mice
treat
rit
treatment
mice
relabel
mab
administ
either
intrasplen
inject
jrcsf
infect
human
pbmc
dramat
reduc
number
cell
similar
result
obtain
treatment
mice
administr
equival
amount
cold
mab
radioisotopecoupl
irrelev
control
mab
reduc
averag
number
infect
cell
detect
scid
mous
spleen
demonstr
efficaci
rit
hiv
provid
proofofprincipl
concept
treat
viral
infect
target
viralinfect
cell
approach
could
potenti
appli
chronic
viral
diseas
like
hepat
c
success
rit
approach
laboratori
studi
combin
earlier
nuclear
medicin
experi
preclin
clinic
studi
show
util
radiolabel
organismspecif
antibodi
imag
infect
review
provid
encourag
feasibl
therapeut
target
microb
label
antibodi
fact
abil
specif
antibodi
local
site
infect
provid
strong
support
potenti
use
techniqu
broad
antimicrobi
strategi
might
possibl
creat
socal
panantibodi
would
recogn
antigen
share
particular
class
human
pathogen
exampl
panantibodi
mab
initi
develop
fungal
melanin
also
bind
synthet
invertebr
cuttlefish
murin
human
melanin
avail
antibodi
would
elimin
necess
antibodi
specif
particular
microorgan
would
enorm
enhanc
develop
rit
infecti
diseas
consid
breadth
research
new
target
microbi
mab
well
vast
need
new
therapeut
modal
infecti
diseas
area
medicin
grow
field
mani
new
approach
improv
efficaci
mab
use
cocktail
mab
combin
mab
exist
drug
synergist
effect
also
mani
new
research
develop
expand
possibl
mab
drug
next
gener
mab
could
develop
novel
target
quorum
sens
molecul
regul
bacteri
growth
virul
factor
express
type
iii
secret
system
use
subset
microb
infect
host
cell
fight
mdr
bacteria
success
approach
target
cellular
efflux
pump
respons
antibiot
resist
gener
type
broadspectrum
mab
enabl
therapeut
mab
develop
could
use
number
microb
thu
extend
market
increas
profit
potenti
bavituximab
exampl
one
mab
specif
phospholipid
expos
inner
surfac
damag
cell
potenti
applic
includ
hiv
hcv
progress
also
made
gener
mab
bispecif
mab
variant
select
bind
multipl
microbi
epitop
final
direct
engin
mab
could
result
enhanc
efficaci
fc
region
alter
extend
serum
halflif
influenc
effector
function
exampl
alter
fc
region
glycosyl
increas
antibodydepend
cellmedi
cytotox
adcc
although
review
focus
use
intact
mab
microbi
diseas
note
microb
fc
region
necessari
efficaci
provid
numer
addit
therapeut
option
exampl
mab
fragment
lack
fc
region
effect
situat
effector
cell
function
necessari
exampl
inhibit
hiv
entri
cautious
optimist
mab
therapeut
revolut
make
much
greater
impact
microbi
diseas
year
ahead
shortag
target
mab
treat
microbi
diseas
time
major
problem
econom
like
success
come
first
nich
area
suffici
need
urgenc
market
size
support
develop
mab
therapi
longer
term
field
need
build
econom
model
suitabl
develop
antibodi
therapi
much
broader
set
microbi
target
